UNITED STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of report (Date of earliest event reported): January 31, 2011

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other

jurisdiction of

incorporation)

(Commission File

Number)

(I.R.S. Employer

Identification No.)

235 East 42nd Street

New York, New York

10017

(Zip

Code)

(Address

of principal executive offices)

Registrant s telephone number, including area code:

(212)

733-2323

Not Applicable

(Former Name or Former Address, if

changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On February 1, 2011, Pfizer Inc. ( Pfizer or Company ) issued a press

release announcing its financial results for the fourth quarter of 2010

and certain other matters. The information contained in the press

release is deemed to be filed under the Securities Exchange Act of

1934 as Exhibit 99 to this report, and such press release is

incorporated herein by reference.

Item 2.05 Costs Associated with Exit or Disposal Activity

On February 1, 2011, the Company announced that it is continuing to

closely evaluate its global research and development function and will

accelerate its current strategies to improve innovation and overall

productivity. Key steps in this process include the planned reduction in

the number of disease areas the Company will focus on as well as a

realigned research and development footprint, including a planned exit

from the Company s Sandwich, U.K. site, subject to customary

requirements, the planned shift of selected resources from the Company s

Groton, Connecticut site to its Cambridge, Massachusetts site, and the

planned outsourcing of certain functions. Attached hereto as Exhibit 99

is the Company s related press release dated February 1, 2011, which is

incorporated by reference herein. These actions were approved by the

Audit Committee of the Company s Board of Directors on January 31, 2011

pursuant to a delegation of authority from the Board, which had reviewed

these actions at several meetings.

In connection with these actions, the Company estimates that:

it will incur total pre-tax exit and disposal charges in the range

of approximately $1.1 billion to $1.6 billion;

such charges will be incurred during 2011 and 2012, with most of

such charges to be incurred in 2011; and

future cash expenditures related to such charges will be in the

range of approximately $1.1 billion to $1.6 billion.

The Company estimates that the total pre-tax exit and disposal charges

referred to above will consist of the following:

employee-termination charges in the range of approximately $800

million to $1.1 billion; and

other exit and implementation charges in the range of approximately

$300 million to $500 million.

Item 2.06 Material Impairments

The first paragraph of Item 2.05 is incorporated by reference herein.

In connection with these actions, the Company will incur impairment and

additional depreciation-asset restructuring charges related to fixed

assets, such as facilities and equipment, including the Sandwich, U.K.

facility. The Company estimates that:

it will incur total pre-tax impairment and additional

depreciation-asset restructuring charges in the range of

approximately $1.1 billion to $1.3 billion, of which approximately

$800 million to $900 million represent additional depreciation-asset

restructuring charges;

such charges will be incurred during 2011 and 2012, with most of

such charges to be incurred in 2011; and

there will be no future cash expenditures related to such charges.

Forward-Looking Information Cautionary Statement

This Current Report on Form 8 K contains forward looking

statements. Pfizer has identified some of these forward-looking

statements with words like will, planned , and estimates , the

negative of these words, other terms of similar meaning or the use of

future dates. Forward-looking statements in this release include,

without limitation, statements regarding the Company s evaluation of its

global research and development function and the anticipated effects

thereof, including estimated exit, disposal, impairment and additional

depreciation-asset restructuring charges. Investors and security

holders are cautioned not to place undue reliance on these

forward-looking statements. Actual results could differ materially from

those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties related to the Company s evaluation of its

global research and development function and the anticipated effects

thereof that could cause results to differ from expectations include,

but are not limited to, the fact that the Company s actual results and

the timing of events could differ materially from those anticipated;

risks related to the Company s ability to implement the initiative as

currently planned; the impact of external matters, including market

conditions; and uncertainties as to the effects of the initiative on the

Company and the potential for unanticipated charges not currently

contemplated that may occur as a result of the initiative. Pfizer

undertakes no obligation to update forward-looking statements as a

result of new information, future developments or otherwise, except as

expressly required by law. All forward-looking statements in this Form

8-K are qualified in their entirety by this cautionary statement.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit 99 -

February 1, 2011, reporting Pfizer's financial results for the

fourth quarter of 2010 and certain other matters. Exhibit 99

is deemed to be filed under the Securities Exchange Act of 1934 in

this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the

registrant has caused this report to be signed on its behalf by the

authorized undersigned.

PFIZER INC.

By:

/s/ Matthew Lepore

Matthew Lepore

Vice President and Corporate Secretary

Chief Counsel Corporate Governance

Dated:

February 1, 2011

EXHIBIT INDEX

Exhibit No.

Description

99

Press Release of Pfizer Inc. dated February 1, 2011, reporting

Pfizer's financial results for the fourth quarter of 2010 and

certain other matters.

-->